The adjustment in price target by Barclays, while maintaining an Overweight rating, suggests a continued positive outlook on Pacira BioSciences but with a slightly reduced growth expectation. This could lead to a neutral short-term impact on the stock as the market digests the new price target against the backdrop of ongoing bullish sentiment.